This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Juvenile Polyarthritis (Seronegative)연소성 다발관절염 (연소성다발관절염)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: M08.3 | Special Copayment Reduction: V133 (rare disease)
B. SynonymsJuvenile polyarthritis (seronegative) | Chronic juvenile polyarthritis
C. Adult onsetLikelihood of first onset in adulthood low — by definition, juvenile polyarthritis (RF-negative type) has onset before age 16, but in many patients active arthritis persists into adulthood, requiring management by an adult rheumatologist.
1. History

Juvenile Rheumatoid Arthritis (JRA) or juvenile idiopathic arthritis (Juvenile Idiopa…

2. Causes

The causes of the juvenile arthritis group of diseases are heterogeneous, and different immunologic mechanisms are involved depending on the disease subtype. In common, genetic…

3. Genetics

The juvenile arthritis group of diseases are complex genetic diseases, and the various genetic risk factors differ by subtype. The most important genetic risk factor is HL…

4. General epidemiology

RF-negative juvenile polyarthritis (M08.3) is the second most common subtype of JIA, accounting for about 20–25% of all JIA. It is more common in girls…

5. Pathophysiology

The pathophysiology of joint inflammation in juvenile arthritis differs by subtype. Common mechanisms include monocytes, macrophages, T cells and B cells within the synovium…

6. Symptoms

The clinical symptoms of RF-negative juvenile polyarthritis are dominated by chronic polyarthritis involving 5 or more joints. Large joints (knees, ankles, wrists, elbo…

7. Signs

On physical examination, joint swelling, warmth, limited range of motion and flexion contractures are the main signs. Longer morning stiffness reflects more severe inflammation. …

8. Screening

Screening for juvenile arthritis is performed in children with joint swelling or morning stiffness persisting for 6 weeks or longer. Basic screening tests include CBC, ESR, CRP,…

9. Diagnosis

The diagnosis of juvenile arthritis is made according to the 2001 revised International League of Associations for Rheumatology (ILAR) classification criteria. Core criteria: onset before age 16, 6 weeks or longer…

10. Treatment

The treatment goals for juvenile arthritis are complete suppression of joint inflammation (targeting remission, treat-to-target), prevention of joint damage and growth impairment, normal development and…

11. Prognosis

The prognosis of RF-negative juvenile polyarthritis is better than that of the RF-positive type, but extensive joint involvement can cause joint damage and functional impairment. Biolog…

12. Prevention

Primary prevention of juvenile arthritis is impossible, but early diagnosis and treatment and prevention of complications are important. Regular ophthalmologic slit-lamp examination in ANA-positive oligoarticular patients…

13. References10 papers in major international journals.

1. History

Juvenile Rheumatoid Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) is an umbrella concept for chronic arthritis occurring in children younger than 16, with a long history and a complex development of classification. The earliest record is the description of chronic arthritis in children by Charles West of England in 1864, and in 1897 George Frederic Still described in detail chronic arthritis in children accompanied by systemic symptoms (fever, rash, lymphadenopathy), and it became known as 'Still disease'.

In the early-to-mid 20th century, childhood arthritis was regarded as a pediatric form of adult rheumatoid arthritis (RA), but immunologic research in the 1970s–80s confirmed that childhood arthritis is a heterogeneous group of diseases considerably different from RA both clinically and immunologically. In 1977, the American College of Rheumatology (ACR) proposed criteria classifying JRA (Juvenile Rheumatoid Arthritis) into 3 onset types (systemic, polyarticular, oligoarticular). In 1994, a European group separately established JCA (Juvenile Chronic Arthritis) criteria.

Subsequently, in 1997–2001, the International League of Associations for Rheumatology (ILAR) integrated these two classifications and proposed a new classification system called JIA (Juvenile Idiopathic Arthritis). The ILAR JIA classification consists of 7 subtypes (systemic, persistent oligoarticular, extended oligoarticular, RF-negative polyarticular, RF-positive polyarticular, psoriatic arthritis, enthesitis-related arthritis, undifferentiated). With the introduction of biologics (etanercept, abatacept, anakinra, tocilizumab, secukinumab, etc.), treatment of JIA has improved greatly since the 2000s.

2. Causes

The causes of the juvenile arthritis group of diseases are heterogeneous, and different immunologic mechanisms are involved depending on the disease subtype. In common, autoimmune or autoinflammatory mechanisms arising from the interaction of genetic predisposition and environmental triggers cause joint inflammation. Reported environmental triggers include viruses (parvovirus B19, rubella, CMV, EBV), bacteria (streptococci, Yersinia) and trauma, but a causal relationship between specific environmental factors and onset has mostly not been established.

In the RF-positive polyarticular type, rheumatoid factor (RF, IgM anti-IgG antibody) and anti-CCP (cyclic citrullinated peptide) antibodies cause joint destruction through autoimmune mechanisms similar to adult RA. In the systemic type (sJIA), as in AOSD, IL-1β-, IL-18- and IL-6-mediated autoinflammatory mechanisms are central. The oligoarticular and RF-negative polyarticular types are characterized by Th1/Th17-mediated intra-articular inflammatory responses and a risk of uveitis associated with ANA positivity. In enthesitis-related arthritis, spondyloarthropathy-type mechanisms associated with HLA-B27 (IL-17, IL-23 pathways) are involved.

3. Genetics

The juvenile arthritis group of diseases are complex genetic diseases, and the various genetic risk factors differ by subtype. The most important genetic risk factor is the HLA (Human Leukocyte Antigen) gene family. In the RF-positive polyarticular type, the HLA-DRB1*04 group (the same as in adult RA) is strongly associated. In the oligoarticular type, HLA-DRB1*01, *08, *11, DQA1*04 and DPB1*03 are associated. In enthesitis-related arthritis, HLA-B27 is a strong risk factor. In the systemic type, HLA associations are weak, and IL-6, IL-18 and NLRP3 polymorphisms have been reported.

As non-HLA risk genes, common autoimmunity genes such as PTPN22, CTLA4, STAT4 and IRF5 are associated with some JIA subtypes. In twin studies, the JIA concordance rate is lower than for monogenic inheritance, suggesting the importance of environmental factors. The significance of genetic counseling is relatively limited; there is a familial clustering risk (sibling relative risk about 15–20-fold), but the absolute risk is low.

4. General epidemiology

RF-negative juvenile polyarthritis (M08.3) is the second most common subtype of JIA, accounting for about 20–25% of all JIA. It is more common in girls (female:male = about 3:1), and the age of onset shows two peaks, in young children (2–4 years) and in adolescence (9–11 years). ANA positivity appears in about 25–40% and is associated with uveitis risk, especially in young girls. The RF-positive polyarticular type (M08.8) accounts for about 5% of JIA and mostly has onset in adolescence. In Korea, registration and treatment are provided through Special Copayment Reduction V133. On long-term follow-up, remission can be achieved in about 30–50%, but in the rest active arthritis persists into adulthood.

5. Pathophysiology

The pathophysiology of joint inflammation in juvenile arthritis differs by subtype. Common mechanisms include infiltration and activation of monocytes, macrophages, T cells and B cells within the synovium, proliferation and angiogenesis of fibroblast-like synoviocytes (FLS) and secretion of cartilage- and bone-destroying enzymes (RANKL, MMP, cathepsin). In the RF-positive polyarticular type, as in adult RA, anti-CCP antibody-mediated immune complexes induce complement activation in the joint, and ACPA (anti-CCP)-specific T cells sustain joint inflammation. In the systemic type, the pathway of NLRP3 inflammasome activation → excessive IL-1β and IL-18 secretion → macrophage activation (MAS risk) is central. In enthesitis-related arthritis, the IL-17/IL-23 axis and HLA-B27-related endoplasmic reticulum stress mechanisms cause enthesis inflammation. In the oligoarticular type, an imbalance of Th17 cells and regulatory T cells results in excessive IL-17 secretion within the joint.

6. Symptoms

The clinical symptoms of RF-negative juvenile polyarthritis are dominated by chronic polyarthritis involving 5 or more joints. Various joints are involved, including large joints (knees, ankles, wrists, elbows), small joints (finger and toe joints) and the cervical spine. Joint pain, swelling, morning stiffness and limited motion are characteristic. Systemic symptoms (fever, rash) are milder than in the systemic type or absent. Cervical joint involvement causes neck pain and limited motion, and especially when there is central oligoarticular involvement, the risk of C1-C2 subluxation should be assessed. Uveitis risk: because asymptomatic anterior uveitis can develop in young ANA-positive girls, regular ophthalmologic slit-lamp examination is essential. Growth delay, joint deformities and muscle atrophy due to chronic polyarticular involvement are long-term complications.

7. Signs

On physical examination, joint swelling, warmth, limited range of motion and flexion contractures are the main signs. Longer morning stiffness reflects more severe inflammation. In the systemic type, daily afternoon fever spikes and a salmon-colored rash (appearing with fever and disappearing with defervescence) are characteristic. When uveitis is present, slit-lamp examination confirms findings of anterior uveitis, and because it is initially asymptomatic, regular ophthalmologic examination for screening is needed. Growth impairment (local or generalized), leg length discrepancy and joint deformities may appear in children with long-standing involvement. Laboratory findings used for diagnosis include elevated ESR and CRP, thrombocytosis, anemia (anemia of chronic disease), RF (positive in the positive polyarticular type) and ANA (positive in about 50–60% of the oligoarticular type).

8. Screening

Screening for juvenile arthritis is performed in children with joint swelling or morning stiffness persisting for 6 weeks or longer. Basic screening tests include CBC, ESR, CRP, RF, ANA, liver and kidney function and uric acid. Because ANA-positive oligoarticular patients have a high risk of uveitis, they are referred immediately for pediatric ophthalmologic slit-lamp examination and screened regularly thereafter. HLA-B27 testing is performed when enthesitis-related arthritis or an ankylosing spondylitis variant is suspected. Anti-CCP antibody testing is used in RF-positive patients or patients with adolescent-onset polyarthritis to assess continuity with adult RA. Joint ultrasound is used to assess clinically unclear joint effusion and synovial thickening.

9. Diagnosis

The diagnosis of juvenile arthritis is made according to the 2001 revised International League of Associations for Rheumatology (ILAR) classification criteria. Core criteria: onset before age 16, arthritis of one or more joints persisting for 6 weeks or longer and exclusion of other causes. Subtype classification is based on the clinical features of the first 6 months of onset (number of joints, RF, ANA, HLA-B27, systemic symptoms). The differential diagnosis includes infectious arthritis (septic, viral), reactive arthritis, rheumatic fever, systemic lupus erythematosus (SLE), seronegative spondyloarthropathy and growing pains. Joint radiography (may be negative early), joint MRI (assessment of early synovial thickening and cartilage and bone damage) and joint ultrasound are used to support diagnosis.

10. Treatment

The treatment goals for juvenile arthritis are complete suppression of joint inflammation (targeting remission, treat-to-target), prevention of joint damage and growth impairment, and ensuring normal development and quality of life. NSAIDs: initial treatment of mild arthritis. Naproxen, ibuprofen, indomethacin. Intra-articular steroid injection: effective for target joints in the oligoarticular type. Triamcinolone hexacetonide preferred. Methotrexate (MTX): the basic DMARD for the polyarticular and extended oligoarticular types. Biologics: with an insufficient response to MTX, etanercept, abatacept, tocilizumab (systemic type), anakinra and canakinumab (systemic type, MAS), secukinumab (enthesitis-related arthritis). Specific to systemic JIA: IL-1 and IL-6 blockade is the first-line biologic treatment. Treatment of uveitis: topical steroids, MTX, adalimumab (TNF blockade). Physical therapy and rehabilitation are key to maintaining joint function.

11. Prognosis

The prognosis of RF-negative juvenile polyarthritis is better than that of the RF-positive type, but extensive joint involvement can cause joint damage and functional impairment. Since the introduction of biologics, remission rates have improved, and etanercept, abatacept and tocilizumab have become standard treatments. Remission before adulthood can be achieved in about 30–50%. In the remaining patients, active arthritis persists into adulthood, requiring transition of care to an adult rheumatologist. When complicated by uveitis, it can progress to cataracts, glaucoma and vision loss without appropriate treatment. When remission is achieved with an early treat-to-target strategy, long-term functional prognosis improves greatly.

12. Prevention

Primary prevention of juvenile arthritis is impossible, but early diagnosis and treatment and prevention of complications are important. In ANA-positive oligoarticular patients, regular ophthalmologic slit-lamp examination (every 4 months to 1 year after onset) detects and treats asymptomatic uveitis early. To prevent joint damage, early complete remission is targeted with a treat-to-target strategy. During immunosuppressive treatment, infections are prevented with vaccination (inactivated vaccines recommended, live vaccines contraindicated). Physical therapy, occupational therapy and sports rehabilitation maintain joint range of motion and muscle strength. Adjustments in school and social environments (education, accommodation in physical activities) are important for supporting the normal development of children.

13. References

  1. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-392. PMID: 14760812.
  2. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767-778. DOI: 10.1016/S0140-6736(07)60363-8. PMID: 17336654.
  3. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis. Arthritis Care Res. 2011;63(4):465-482. DOI: 10.1002/acr.20459. PMID: 21452260.
  4. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202-1209. PMID: 9214419.
  5. Wallace CA, Ruperto N, Giannini EH. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2290-2294. PMID: 15517650.
  6. Gowdie PJ, Tse SM. Juvenile idiopathic arthritis. Pediatr Clin North Am. 2012;59(2):301-327. DOI: 10.1016/j.pcl.2012.03.014. PMID: 22560573.
  7. Klein A, Minden K, Hospach A, et al. Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis. Ann Rheum Dis. 2020;79(7):969-974. DOI: 10.1136/annrheumdis-2019-216579. PMID: 32350026.
  8. Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658-666. DOI: 10.1002/art.24516. PMID: 19405003.
  9. Nigrovic PA, Mannion M, Prince FHM, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2011;63(2):545-555. DOI: 10.1002/art.30128. PMID: 21280009.
  10. Horneff G, De Buck M, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68(4):519-525. DOI: 10.1136/ard.2007.087593. PMID: 18445619.